ASH 2022 | Managing cardiotoxicity associated with the use of ibrutinib
Nirav Niranjan Shah
• 9 Dec 2022
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, talks on ibrutinib-associated cardiotoxicity, highlighting management strategies and the potential of switching to a second-generation BTK inhibitor. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Miltenyi Biotec: Consultancy, Research Funding; Lilly Oncology: Consultancy, Honoraria; Epizyme: Consultancy; Bristol Myers Squibb: Consultancy; Incyte Corporation: Consultancy, Honoraria, Speakers Bureau; TG therapeutics: Consultancy; Kite Pharma: Consultancy.
